Matthew Pillar

Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/

ARTICLES BY MATTHEW PILLAR

Mastery Of The mAb
Inside Homology Medicines’ Decision To Build
The Next Pandemic: Biopharma’s Opportunities & Obligations
Beyond Parenteral: Alternative Administration Of Biologics Shows Promise
The “Digitization” Of Therapeutics
Flexible Manufacturing & Single Use: A Story Of Love And Hate
Democratizing Biologics With Brian Finrow, J.D., And Craig Behnke, Ph.D.
Adaptive, Precision Trials Change The Clinical Paradigm
Navigating CDMO Capacities & Capabilities
AION Labs’ Challenge To AI Drug Development Innovators
Developability: Making Better Bets On Biologic Winners
Slippery Slope: Competitive Differentiation In Biopharma
Inside Aruvant’s Gene Therapy Manufacturing Strategy
mAb 2.0 For Psoriatic Arthritis
Big Bio: Inside SILS’ New Stake In Biocon
4 Keys To Winning FDA Breakthrough Therapy Designation
New ADC Linker Tech Shows Efficacy, Safety Advantages
Inside KKNA’s Uncommon D&I Success
Resetting The Immune System With Protein Therapeutics
Alzheimer’s Therapy Takes A Cue From Oncology
Cell Therapy Logistics: Challenged By COVID-19
The Precarious Promise Of Biopharma PR
Physics To Genetics: New Treatments For Hereditary Heart Disease
Developing A Cure For Diabetes Type 1
What’s Behind BridgeBio’s 30+ Drug Candidates?